UPDATE 1-Acorda's MS walking drug Q4 sales view beats Street
* Sees Q4 Ampyra sales of $55.7 mln
* Sees FY gross sales of $141.4 mln vs est $185.12 mln
* Shares up as much as 9 percent
Jan 10 (Reuters) - Acorda Therapeutics Inc (ACOR.O) forecast better-than-expected quarterly sales view for its drug to treat walking difficulties in patients with multiple sclerosis, sending its shares up 9 percent.
The pharmaceutical company said it expects fourth-quarter sales of $55.7 million from its key drug Ampyra.
In November, Acorda had warned of a decrease in sales for Ampyra, as the number of new patients starting on the drug, which was launched in March, would no longer be augmented by patients from the backlog. [ID:nSGE6A00FY]
Analysts have, since then, revised fourth-quarter sales expectation of Ampyra to $44-$50 million.
The Hawthorne, New York-based company also said it sees gross sales of $141.4 million for the year.
Analysts, on an average, were expecting revenue of $185.12 million for the year, according to Thomson Reuters I/B/E/S.
Acorda shares, which have risen 10 percent since its warning on lower Ampyra sales, were up 7 percent at $29.48 on Monday on Nasdaq. (Reporting by Vidya L Nathan in Bangalore; Editing by Roshni Menon)
- Merkel says tightening Ukraine-Russian border is key to peace deal |
- China rejects U.S. criticism over jet encounter
- Protesters mark two weeks since police shooting in Ferguson, Missouri |
- U.S. hostage rescuers dropped from night sky: Syria activist
- Gaza gunmen execute 'collaborators'; mortar kills Israeli boy |